BACKGROUND: Identification of tumour predisposition syndromes in patients who have cancer in childhood is paramount for optimal care. A screening instrument that can help to identify such patients will facilitate physicians caring for children with cancer. The complete screening instrument should consist of a standardised series of pictures and a screening form for manifestations not visible in the pictures. Here we describe the development of such a screening form based on an international two-stage Delphi process and an initial validation of the complete instrument. PATIENTS AND METHODS: We identified manifestations that may contribute to the diagnosis of a tumour predisposition syndrome through the Winter-Baraitser Dysmorphology Database and the textbook "Gorlin's Syndromes of the Head and Neck". In a two-round Delphi process, eight international content-experts scored the contribution of each of these manifestations. We performed a clinical validation of the instrument in a selected cohort of 10 paediatric cancer patients from another centre. RESULTS: In total, 49 manifestations were found to contribute to the diagnosis of a tumour predisposition syndrome and were included in the screening form. The pilot validation study showed that patients suspected of having a tumour predisposition syndrome were recognised. Excellent correlation for indications of patient's referral between the screening instrument and the reference standard (personal evaluation by an experienced clinical geneticist) was found. CONCLUSIONS: The Delphi process performed by international specialists with a function as opinion leaders in their field of expertise, has led to a screening instrument for childhood cancer patients. Patients who may have a tumour predisposition syndrome and thus have an indication to be referred for further genetic analysis, can be identified using the screening instrument.
BACKGROUND: Identification of tumour predisposition syndromes in patients who have cancer in childhood is paramount for optimal care. A screening instrument that can help to identify such patients will facilitate physicians caring for children with cancer. The complete screening instrument should consist of a standardised series of pictures and a screening form for manifestations not visible in the pictures. Here we describe the development of such a screening form based on an international two-stage Delphi process and an initial validation of the complete instrument. PATIENTS AND METHODS: We identified manifestations that may contribute to the diagnosis of a tumour predisposition syndrome through the Winter-Baraitser Dysmorphology Database and the textbook "Gorlin's Syndromes of the Head and Neck". In a two-round Delphi process, eight international content-experts scored the contribution of each of these manifestations. We performed a clinical validation of the instrument in a selected cohort of 10 paediatric cancerpatients from another centre. RESULTS: In total, 49 manifestations were found to contribute to the diagnosis of a tumour predisposition syndrome and were included in the screening form. The pilot validation study showed that patients suspected of having a tumour predisposition syndrome were recognised. Excellent correlation for indications of patient's referral between the screening instrument and the reference standard (personal evaluation by an experienced clinical geneticist) was found. CONCLUSIONS: The Delphi process performed by international specialists with a function as opinion leaders in their field of expertise, has led to a screening instrument for childhood cancerpatients. Patients who may have a tumour predisposition syndrome and thus have an indication to be referred for further genetic analysis, can be identified using the screening instrument.
Authors: Patricia Q McGinnis; Susan F Wainwright; Laurita M Hack; Kim Nixon-Cave; Susan Michlovitz Journal: Physiother Theory Pract Date: 2010-08 Impact factor: 2.279
Authors: Judith E Allanson; Christopher Cunniff; H Eugene Hoyme; Julie McGaughran; Max Muenke; Giovanni Neri Journal: Am J Med Genet A Date: 2009-01 Impact factor: 2.802
Authors: Leslie G Biesecker; Jon M Aase; Carol Clericuzio; Fiorella Gurrieri; I Karen Temple; Helga Toriello Journal: Am J Med Genet A Date: 2009-01 Impact factor: 2.802
Authors: John C Carey; M Michael Cohen; Cynthia J R Curry; Koenraad Devriendt; Lewis B Holmes; Alain Verloes Journal: Am J Med Genet A Date: 2009-01 Impact factor: 2.802
Authors: Alasdair Hunter; Jaime L Frias; Gabriele Gillessen-Kaesbach; Helen Hughes; Kenneth Lyons Jones; Louise Wilson Journal: Am J Med Genet A Date: 2009-01 Impact factor: 2.802
Authors: Raoul C M Hennekam; Valerie Cormier-Daire; Judith G Hall; Károly Méhes; Michael Patton; Roger E Stevenson Journal: Am J Med Genet A Date: 2009-01 Impact factor: 2.802
Authors: O P Geerse; K Wynia; M Kruijer; M J Schotsman; T J N Hiltermann; A J Berendsen Journal: Support Care Cancer Date: 2016-10-14 Impact factor: 3.603
Authors: Floor A M Postema; Saskia M J Hopman; Corianne A J M de Borgie; Peter Hammond; Raoul C Hennekam; Johannes H M Merks; Cora M Aalfs; Jakob K Anninga; Lieke Pv Berger; Fonnet E Bleeker; Eveline Sjm de Bont; Corianne Ajm de Borgie; Charlotte J Dommering; Natasha Ka van Eijkelenburg; Peter Hammond; Raoul C Hennekam; Marry M van den Heuvel-Eibrink; Saskia Mj Hopman; Marjolijn Cj Jongmans; Wijnanda A Kors; Tom Gw Letteboer; Jan Lcm Loeffen; Johannes Hm Merks; Maran Jw Olderode-Berends; Floor Am Postema; Anja Wagner Journal: BMJ Open Date: 2017-01-20 Impact factor: 2.692
Authors: Raoul C Hennekam; Johannes H M Merks; Floor A M Postema; Saskia M J Hopman; Corianne A J M de Borgie; Cora M Aalfs; Jakob K Anninga; Lieke P V Berger; Fonnet E Bleeker; Charlotte J Dommering; Natasha K A van Eijkelenburg; Peter Hammond; Marry M van den Heuvel-Eibrink; Janna A Hol; Wijnanda A Kors; Tom G W Letteboer; Jan L C M Loeffen; Lisethe Meijer; Maran J W Olderode-Berends; Anja Wagner Journal: Fam Cancer Date: 2021-03-09 Impact factor: 2.375